Anticonvulsive Effects and Pharmacokinetic Profile of Cannabidiol (CBD) in the Pentylenetetrazol (PTZ) or N-Methyl-D-Aspartate (NMDA) Models of Seizures in Infantile Rats

• Published in: International Journal of Molecular Sciences Vol. 23; no. 1; p. 94
• Main Authors: Uttl, Libor, Hložek, Tomáš, Mareš, Pavel, Páleníček, Tomáš, Kubová, Hana
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 22.12.2021; MDPI
• Subjects: Age groups; Animals; Anticonvulsants; Anticonvulsants - pharmacology; Brain; Brain - drug effects; Cannabidiol; Cannabidiol - pharmacokinetics; Cannabidiol - pharmacology; cannabidiol; epilepsy; seizures; NMDA; pentylentetrazole; PTZ; immature rats; Convulsions & seizures; Disease Models, Animal; Drug dosages; Epilepsy; Epilepsy - drug therapy; Laboratory animals; Male; N-Methylaspartate; N-Methylaspartate - pharmacology; Newborn babies; Pediatrics; Pentylenetetrazole; Pentylenetetrazole - pharmacology; Pharmacokinetics; Rats; Rats, Wistar; Seizures; Seizures - drug therapy; cannabidiol; epilepsy; PTZ; NMDA; seizures; immature rats; pentylentetrazole

In spite of use of cannabidiol (CBD), a non-psychoactive cannabinoid, in pediatric patients with epilepsy, preclinical studies on its effects in immature animals are very limited. In the present study we investigated anti-seizure activity of CBD (10 and 60 mg/kg administered intraperitoneally) in tw...